|
|
|
|
GE’s $100M healthymagination challenge
|
GE’s healthymagination Challenge is an open call to action seeking ideas to accelerate early detection and enable more personalized treatment for breast cancer.
Through the challenge, GE and its venture partners will award up to $100 million to fund breakthrough ideas that advance early detection, more accurate diagnosis and targeted treatment of breast cancer.
|
Accelerating breast cancer diagnostic innovation
|
Understanding the complexity of breast cancer, the healthymagination Challenge will be separated into multiple phases.
The initial phase of the Challenge will focus on two areas:
1. Breast cancer pathways: Map breast cancer pathways independent of classic hormone dependent signaling and how those pathways relate to “triple negative” breast cancer (her 2, estrogen and progesterone receptor negative) – identify possible diagnostics and potential targeted treatments.
2. Molecular similarities between tumors: Map the molecular/proteomic similarities between breast cancer and other solid tumors especially as it relates to the establishment of a tissue independent classification of cancer and pathway centric therapeutic intervention
We are seeking innovative solutions to improve identification of effective therapies and diagnostic tools based on an individual’s unique tumor, as well as innovations that uncover cancer tumor similarities at a molecular level - helping guide the development of improved therapies.
|
The first phase of the Challenge is open till November 20, with winners being announced in Q1 2012. You can submit your innovative solutions at healthymagination.com/challenge.
GE and its VC partners will also plan to launch a second phase of the healthymagination Challenge in early 2012.
|
| Entries will be evaluated as candidates for both a potential commercial relationship as well as a $100,000 innovation seed grant. Ideas considered for a future commercial relationship will be evaluated by a committee of representatives from GE businesses and the Challenge venture capital partners, Kleiner Perkins Caufield & Byers, Mohr Davidow Ventures, Venrock and MPM Capital. A separate, independent judging panel - consisting of GE executives, venture capital partners and several leading healthcare luminaries, including former U.S. FDA Commissioner and National Cancer Institute Director, Dr. Andrew Von Eschenbach; Professor of Surgery and Director of the University of Michigan Breast Care Center, Dr. Lisa Newman; and cancer medicine specialist and Imperial College’s professor of cancer medicine, Dr. Justin Stebbing - will select recipients of the cash awards. |
 |
|
|
|
